The Weekly Recap 9/25/26: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni receive new funding, achieve regulatory approvals, appoint new executives, receive awards, and much more on the road to LSI Europe ‘26 in Barcelona (September 28 - October 1).

Anaconda Biomed

Closed a $56M financing led by Omega Funds, with participation from new investor Spain’s Co-investment Fund (FOCO), managed by COFIDES, alongside Asabys Partners, Ysios Capital, CDTI Innovación, and other investors. The funding will support product development and clinical work, including completion of the ATHENA pivotal IDE study evaluating the ANA Funnel Catheter, while advancing its Funnel Catheter platform designed to improve clot capture, reduce embolic complications, and maximize brain reperfusion.

Biolinq

Received FDA 510(k) clearance for over-the-counter use of Biolinq Shine™, the company’s needle-free glucose sensor designed to provide a simple, intuitive view of glucose, activity, and sleep information in a single device with autonomous operation. The forearm-worn device features an integrated primary display that operates with or without a phone and uses a color-coded LED to communicate real-time glucose changes.

CAIRDAC

Appointed LSI Alumni Raymond W. Cohen. Cohen, an accredited public company director and accomplished medical technology executive, has over four decades of medtech industry experience, including being the co-founder and CEO of Axonics.

Cordis

Received FDA Approval for its SELUTION SLR™ Drug-Eluting Balloon (DEB) to treat coronary in-stent restenosis (ISR). SELUTION SLR DEB gives physicians a way to treat ISR by delivering sustained sirolimus therapy without leaving a permanent implant behind.

Dialybrid

Raised a €15M Series A round led by XGEN Venture, with the participation of CDP Venture Capital (Rilancio Fund). The financing will fund the clinical validation of Dialybrid’s Silkothane^® Arteriovenous Graft as a hemodialysis vascular access and the preclinical development of the proprietary Silkothane^® material in other vascular applications.

Epitel

Selected by the FDA to participate in the READI-Home Innovation Challenge. The company's REMI™ Neuro Monitoring Home Health Hub is a wireless wearable EEG system designed for extended-duration monitoring in home and ambulatory settings, with the goal of supporting care after hospital discharge and reducing avoidable readmissions.

FIZE Medical

Announced the first close of its Series B financing round, co-led by Asahi Kasei Medical and Rapha Capital Management, advancing toward its $20M financing target. The funding will support expansion of the company’s commercial footprint and development of the next-generation FIZE Optima platform toward predictive, AI-guided clinical decision support.

GT Metabolic Solutions

Received FDA clearance of its expanded GT Linear Magnet platform and indication to include the company’s new 60mm and 70mm Magnets for side-to-side gastroileostomy and gastrojejunostomy. The company is continuing to expand the applications of Magnetic Surgery and aims to bring new possibilities to surgeons and their patients.

HighLife

Successfully completed an €80M financing round co-led by Andera Partners, Sofinnova Partners, Supernova Invest, and Mérieux Equity Partners, with participation from new and existing investors. The funding will accelerate the company's commercial expansion across Europe and advance its U.S. clinical development program.

illumicell AI

Welcomed Andrew Ward as its Head of Hardware Development. Ward brings deep experience across Medical Imaging, optics, electromechanical systems, and FDA-regulated diagnostics.

Lenoss Medical

Surpassed 500 OsteoPearl^® procedures, with more than half of those procedures occurring in the last 12 months. OsteoPearl is a novel biological allograft implant made from 100% cortical bone, providing a scaffold for the ongrowth and/or ingrowth of newly formed bone. 

MMI - Medical Microinstruments

Received a new €17M investment from Angelini Ventures, with participation from the European Investment Bank (EIB). The company’s Symani system combines the world's smallest wristed microinstruments with motion scaling and tremor reduction to enable microsurgery and supermicrosurgery on structures as small as 0.1mm.

NOVADIP Biosciences

Received €10.4M in financing led by New Science Ventures, with participation from existing investors FundPlus, Wallonie Entreprendre, VIVES Partners, ORSA, Sambrinvest, Noshaq, and invest.bw. The funds will be used to advance its lead program, NVD003, an autologous cell-based therapy, through the final stage of clinical development and preparation for regulatory submission.

PRECISIS

Recognized by the European Investment Bank (EIB) with the Innovation Champion Award. The company’s lead product, EASEE^®, is a targeted, reversible neurostimulation therapy for people with drug-resistant focal epilepsy.

Respiree

Extended its Series A financing round with participation from ARKRAY & PARTNERS and Bizedge Capital, alongside lead investors We Venture Capital and ClavystBio, and existing investors. The expanded funding will support the growth of the company’s global commercial team and strengthen its presence in the U.S. through its expansion from the Texas Medical Center Innovation in Houston.

SamanTree Medical

Launched a commercial partnership with BOLD MedTech France to support the deployment of the Histolog Scanner and Histolog Remote across leading French hospitals and private clinics. Stéphane Perales of BOLD MedTech France will focus on accelerating clinical adoption, strengthening relationships with surgical and pathology teams, and expanding our footprint in intraoperative tissue imaging.

Teal Health

Closed its Series A funding round, led by .406 Ventures, with continued backing from Emerson Collective, Forerunner, Serena Ventures, Metrodora Ventures, and existing partners. The company is developing the Teal Wand, the first and most accurate FDA-authorized at-home HPV self-collection device, aiming to help more women get screened for cervical cancer by eliminating the barriers that kept women from prioritizing their care.

THINK Surgical

Appointed Rick McDowell as Vice President, Sales. McDowell brings more than 20 years of experience in medical device commercialization, clinical strategy, and capital sales, with a career spent building and leading high-performing sales, clinical, and marketing teams across the surgical robotics industry.

UltraSight

Raised a $24M Series B2 financing round, led by Alive HealthTech Growth Fund, with participation from Deep Insight, Star51 Capital, Connecticut Innovations, eHealth Ventures, Mayo Clinic Ventures, NYU, and Iron Nation. The financing will support the company’s continued commercial expansion in the U.S. and the development of new workflows for intensive care and circulatory support settings, where time-critical cardiac imaging can directly inform patient management.

Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.